IT201900025414A1 - Composto per il trattamento della sindrome emolitico uremica - Google Patents

Composto per il trattamento della sindrome emolitico uremica

Info

Publication number
IT201900025414A1
IT201900025414A1 IT102019000025414A IT201900025414A IT201900025414A1 IT 201900025414 A1 IT201900025414 A1 IT 201900025414A1 IT 102019000025414 A IT102019000025414 A IT 102019000025414A IT 201900025414 A IT201900025414 A IT 201900025414A IT 201900025414 A1 IT201900025414 A1 IT 201900025414A1
Authority
IT
Italy
Prior art keywords
hemolitic
uremic
syndrome
compound
treatment
Prior art date
Application number
IT102019000025414A
Other languages
English (en)
Inventor
Maurizio Brigotti
Domenica Carnicelli
Elisa Porcellini
Elisabetta Galassi
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Priority to IT102019000025414A priority Critical patent/IT201900025414A1/it
Priority to JP2022539066A priority patent/JP2023508979A/ja
Priority to EP20829373.8A priority patent/EP4081236A1/en
Priority to CA3163030A priority patent/CA3163030A1/en
Priority to BR112022012581A priority patent/BR112022012581A2/pt
Priority to PCT/IB2020/062405 priority patent/WO2021130700A1/en
Priority to US17/788,688 priority patent/US20230053129A1/en
Publication of IT201900025414A1 publication Critical patent/IT201900025414A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IT102019000025414A 2019-12-23 2019-12-23 Composto per il trattamento della sindrome emolitico uremica IT201900025414A1 (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IT102019000025414A IT201900025414A1 (it) 2019-12-23 2019-12-23 Composto per il trattamento della sindrome emolitico uremica
JP2022539066A JP2023508979A (ja) 2019-12-23 2020-12-23 溶血性尿毒症症候群を処置するための化合物
EP20829373.8A EP4081236A1 (en) 2019-12-23 2020-12-23 Compound for the treatment of the hemolytic-uremic syndrome
CA3163030A CA3163030A1 (en) 2019-12-23 2020-12-23 Compound for the treatment of the hemolytic-uremic syndrome
BR112022012581A BR112022012581A2 (pt) 2019-12-23 2020-12-23 Composto para o tratamento da síndrome hemolítico-urêmica
PCT/IB2020/062405 WO2021130700A1 (en) 2019-12-23 2020-12-23 Compound for the treatment of the hemolytic-uremic syndrome
US17/788,688 US20230053129A1 (en) 2019-12-23 2020-12-23 Compound for the treatment of the hemolytic-uremic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000025414A IT201900025414A1 (it) 2019-12-23 2019-12-23 Composto per il trattamento della sindrome emolitico uremica

Publications (1)

Publication Number Publication Date
IT201900025414A1 true IT201900025414A1 (it) 2021-06-23

Family

ID=70009322

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000025414A IT201900025414A1 (it) 2019-12-23 2019-12-23 Composto per il trattamento della sindrome emolitico uremica

Country Status (7)

Country Link
US (1) US20230053129A1 (it)
EP (1) EP4081236A1 (it)
JP (1) JP2023508979A (it)
BR (1) BR112022012581A2 (it)
CA (1) CA3163030A1 (it)
IT (1) IT201900025414A1 (it)
WO (1) WO2021130700A1 (it)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045469A1 (en) 2015-01-15 2016-07-20 Northern Antibiotics Oy Polymyxin derivative and uses thereof
WO2018172733A1 (en) * 2017-03-23 2018-09-27 Helperby Therapeutics Limited Combinations of polymyxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045469A1 (en) 2015-01-15 2016-07-20 Northern Antibiotics Oy Polymyxin derivative and uses thereof
WO2018172733A1 (en) * 2017-03-23 2018-09-27 Helperby Therapeutics Limited Combinations of polymyxins

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
ARFILLI ET AL., BIOCHEM. J., vol. 432, 2010, pages 173 - 180
ARFILLI ET AL., TOXINS (BASEL, vol. 7, 2015, pages 4564 - 4576
BANNATYNE ET AL., J. INFECT. DIS., vol. 136, 1977, pages 469 - 474
BAUWENS ET AL., THROMB. HAEMOST., vol. 105, 2011, pages 515 - 528
BRIGOTTI ET AL., J IMMUNOL., vol. 191, 2013, pages 4748 - 4758
BRIGOTTI ET AL., THROMBOSIS AND HAEMOSTASIS, 2019
CARNICELLI ET AL., J. IMMUNOL., vol. 196, 2016, pages 1177 - 1185
FRIEDRICH ET AL., J INFECT. DISEASES, vol. 185, 2002, pages 74 - 84
KARPMAN ET AL., BLOOD, vol. 97, 2001, pages 3100 - 3108
MACHER ET AL., J. BIOL. CHEM., vol. 255, 1980, pages 2092 - 2096
MARTTI VAARA ET AL: "Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY., vol. 73, no. 2, 1 February 2018 (2018-02-01), GB, pages 452 - 455, XP055722159, ISSN: 0305-7453, DOI: 10.1093/jac/dkx394 *
MORRISON ET AL., IMMUNOCHEMISTRY, vol. 13, 1976, pages 813 - 818
OIE S ET AL: "IN VITRO SUSCEPTIBILITY OF ESCHERISCHIA COLI O157 TO SEVERAL ANTIMICROBIAL AGENTS", BIOLOGICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 20, no. 5, 1 May 1997 (1997-05-01), pages 584/585, XP000656149, ISSN: 0918-6158 *
PATON E PATON, CLIN. MICROBIOL. REV., vol. 11, 1998, pages 450 - 479
SCHEUTZ ET AL., EURO. SURVEILL., vol. 16, 2011
SRIMAL ET AL., BIOCHEM. J., vol. 315, 1996, pages 679 - 686
STAHL ET AL., BLOOD, vol. 117, 2011, pages 5503 - 5513
STAHL ET AL., PLOS ONE, vol. 4, 2009, pages e6990
TARR ET AL., LANCET, vol. 365, 2005, pages 1073 - 1086
TARR P I ET AL: "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 365, no. 9464, 19 March 2005 (2005-03-19), pages 1073 - 1086, XP027764646, ISSN: 0140-6736, [retrieved on 20050319] *
TAZZARI ET AL., CYTOMETRY B CLIN. CYTOM., vol. 61, 2004, pages 40 - 44
VAARA ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 54, 2010, pages 3341 - 3346
VAARA ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 52, 2008, pages 3229 - 3236
VAARA ET AL., PEPTIDES, vol. 91, 2017, pages 8 - 12
VAARA MARTTI ET AL: "Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 91, 11 March 2017 (2017-03-11), pages 8 - 12, XP085026939, ISSN: 0196-9781, DOI: 10.1016/J.PEPTIDES.2017.03.002 *
VAARA, J. ANTIMICROB. CHEMOTHER., vol. 68, 2013, pages 1213 - 1219
VAARA, M., CURR. OPIN. MICROBIOL., vol. 13, 2010, pages 574 - 581
VAN SETTEN ET AL., BLOOD, vol. 88, 1996, pages 174 - 183
WURZNER ET AL., SEMIN THROMB HEMOST., vol. 40, 2014, pages 508 - 516

Also Published As

Publication number Publication date
WO2021130700A1 (en) 2021-07-01
EP4081236A1 (en) 2022-11-02
JP2023508979A (ja) 2023-03-06
WO2021130700A8 (en) 2021-12-30
BR112022012581A2 (pt) 2022-09-06
US20230053129A1 (en) 2023-02-16
CA3163030A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
IL284363A (en) RNA editing oligonucleotides for the treatment of Asher syndrome
DK3740504T5 (da) CD70 kombinationsterapi
IL268125A (en) Pridopidine for the treatment of fragile x syndrome
DK3870578T3 (da) Terapeutiske forbindelser
IL292657A (en) Therapeutic history of interleukin-22
EP3593803A4 (en) COMPOUNDS FOR TREATING DISEASES CAUSED BY OXALATE ACCUMULATION
DK3749336T3 (da) Sårbehandlingsgel opnåelig ved at kombinere blodpladerigt plasma med autolog-afledt thrombin
IL290178A (en) Ube3a for the treatment of Engelmann syndrome
EP3737703A4 (en) TREATMENT OF FRAGILE X SYNDROME
IT201900025414A1 (it) Composto per il trattamento della sindrome emolitico uremica
IL290319A (en) Compound for combined treatment
IT201700086482A1 (it) Composizione per il trattamento della vaginosi batterica
ITUA20163025A1 (it) Composizione per il trattamento della sindrome dell’ovaio policistico
EP3890731A4 (en) COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
GB201908885D0 (en) Therapeutic compounds
IL290404A (en) Treatment for fragile x syndrome
HUE062594T2 (hu) Vakolatkezelõ anyag
ES1230454Y (es) Férula nasal dual
UA43922S (uk) Лава
IT201700108039A1 (it) Composizione per il trattamento della costipazione
IT201700108033A1 (it) Composizione per il trattamento della costipazione
DE112020004733A5 (de) Oberflächenbehandlungsverfahren
IL284749A (en) Treatment of Pitt-Hopkins syndrome
UA41274S (uk) Масажер
IT201700123899A1 (it) Uso del fenoldopam per il trattamento della sindrome emolitico uremica